JPS6191116A - 安定化された注射用ピロキシカム液剤 - Google Patents

安定化された注射用ピロキシカム液剤

Info

Publication number: JPS6191116A
Authority: JP; Japan
Prior art keywords: piroxicam; solution; volume; methylglucamine; ethanol
Prior art date: 1984-10-10
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Granted

Application number

JP60224617A

Other languages

English (en)

Japanese (ja)

Other versions

JPH03849B2 (2

Inventor

ヴアルター・フリーズ

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

HEINRICH MC NATSUHAFUORUGERU

MACK CHEM PHARM

Original Assignee

HEINRICH MC NATSUHAFUORUGERU

MACK CHEM PHARM

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1984-10-10

Filing date

1985-10-08

Publication date

1986-05-09

1985-10-08 Application filed by HEINRICH MC NATSUHAFUORUGERU, MACK CHEM PHARM filed Critical HEINRICH MC NATSUHAFUORUGERU

1986-05-09 Publication of JPS6191116A publication Critical patent/JPS6191116A/ja

1991-01-09 Publication of JPH03849B2 publication Critical patent/JPH03849B2/ja

Status Granted legal-status Critical Current

Links

229960002702 piroxicam Drugs 0.000 title claims description 57
QYSPLQLAKJAUJT-UHFFFAOYSA-N piroxicam Chemical compound OC=1C2=CC=CC=C2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 QYSPLQLAKJAUJT-UHFFFAOYSA-N 0.000 title claims description 57
239000007788 liquid Substances 0.000 title claims 2
238000002347 injection Methods 0.000 title description 5
239000007924 injection Substances 0.000 title description 5
229940079593 drug Drugs 0.000 title description 2
239000003814 drug Substances 0.000 title description 2
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 37
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 26
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims description 19
239000002904 solvent Substances 0.000 claims description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
239000004480 active ingredient Substances 0.000 claims description 3
239000000243 solution Substances 0.000 description 44
235000013772 propylene glycol Nutrition 0.000 description 10
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
239000007864 aqueous solution Substances 0.000 description 7
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 6
239000003960 organic solvent Substances 0.000 description 6
238000003756 stirring Methods 0.000 description 6
239000000126 substance Substances 0.000 description 6
238000000034 method Methods 0.000 description 5
ICSNLGPSRYBMBD-UHFFFAOYSA-N 2-aminopyridine Chemical group NC1=CC=CC=N1 ICSNLGPSRYBMBD-UHFFFAOYSA-N 0.000 description 4
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
239000003708 ampul Substances 0.000 description 4
239000012154 double-distilled water Substances 0.000 description 4
239000000203 mixture Substances 0.000 description 4
229940102223 injectable solution Drugs 0.000 description 3
238000002156 mixing Methods 0.000 description 3
239000008194 pharmaceutical composition Substances 0.000 description 3
150000003839 salts Chemical class 0.000 description 3
235000011121 sodium hydroxide Nutrition 0.000 description 3
238000003860 storage Methods 0.000 description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
239000003125 aqueous solvent Substances 0.000 description 2
239000002152 aqueous-organic solution Substances 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
230000008025 crystallization Effects 0.000 description 2
229910001873 dinitrogen Inorganic materials 0.000 description 2
239000012153 distilled water Substances 0.000 description 2
239000000463 material Substances 0.000 description 2
239000003791 organic solvent mixture Substances 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 description 2
DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
-1 1-hytroquine-2- Chemical compound 0.000 description 1
DSXUKALFCJHHBV-UHFFFAOYSA-N 2-methyl-n-pyridin-2-yl-1,2-benzothiazine-3-carboxamide Chemical compound CN1SC2=CC=CC=C2C=C1C(=O)NC1=CC=CC=N1 DSXUKALFCJHHBV-UHFFFAOYSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
229940111133 antiinflammatory and antirheumatic drug oxicams Drugs 0.000 description 1
239000013040 bath agent Substances 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000036765 blood level Effects 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000003518 caustics Substances 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
230000000694 effects Effects 0.000 description 1
238000011049 filling Methods 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
239000008141 laxative Substances 0.000 description 1
230000002475 laxative effect Effects 0.000 description 1
239000012669 liquid formulation Substances 0.000 description 1
239000003509 long acting drug Substances 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000012046 mixed solvent Substances 0.000 description 1
XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 description 1
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
125000000962 organic group Chemical group 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000011877 solvent mixture Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Dermatology (AREA)
Engineering & Computer Science (AREA)
Rheumatology (AREA)
Organic Chemistry (AREA)
Pain & Pain Management (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Finger-Pressure Massage (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)

JP60224617A 1984-10-10 1985-10-08 安定化された注射用ピロキシカム液剤 Granted JPS6191116A (ja)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE3437232.6		1984-10-10
DE19843437232 DE3437232A1 (de)	1984-10-10	1984-10-10	Stabilisierte injektionsloesungen von piroxicam

Publications (2)

Publication Number	Publication Date
JPS6191116A true JPS6191116A (ja)	1986-05-09
JPH03849B2 JPH03849B2 (2)	1991-01-09

Family

ID=6247603

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
JP60224617A Granted JPS6191116A (ja)	1984-10-10	1985-10-08	安定化された注射用ピロキシカム液剤

Country Status (22)

Country	Link
US (1)	US4628053A (2)
EP (1)	EP0177870B1 (2)
JP (1)	JPS6191116A (2)
KR (1)	KR890001001B1 (2)
CN (1)	CN85107838B (2)
AT (1)	ATE62416T1 (2)
AU (1)	AU557184B2 (2)
CA (1)	CA1251734A (2)
DD (1)	DD238329A5 (2)
DE (2)	DE3437232A1 (2)
DK (1)	DK165901C (2)
FI (1)	FI84315C (2)
GR (1)	GR852439B (2)
HU (1)	HU195111B (2)
IE (1)	IE58267B1 (2)
IL (1)	IL76624A0 (2)
NO (1)	NO166687C (2)
NZ (1)	NZ213758A (2)
PH (1)	PH23058A (2)
PT (1)	PT81264B (2)
SU (1)	SU1482509A3 (2)
ZA (1)	ZA857783B (2)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1998001138A1 (fr) *	1996-07-04	1998-01-15	Nippon Kayaku Kabushiki Kaisha	Injections de succinate sodique de methylprednisolone
JP2003535902A (ja) *	2000-06-20	2003-12-02	ベーリンガーインゲルハイムフェトメディカゲゼルシャフトミットベシュレンクテルハフツング	安定な高濃度メロキシカム溶液
JP2005511720A (ja) *	2001-12-12	2005-04-28	ベーリンガーインゲルハイムフェトメディカゲゼルシャフトミットベシュレンクテルハフツング	無針注射用の安定な高濃度メロキシカム溶液
JP2009539984A (ja) *	2006-06-12	2009-11-19	テバファーマシューティカルインダストリーズリミティド	安定性ラキニモド製剤
JP2010180152A (ja) *	2009-02-05	2010-08-19	Zeria Pharmaceut Co Ltd	コロソリン酸含有水性液剤

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2545910B1 (fr) *	1983-05-11	1988-07-22	Valeo	Dispositif pour ameliorer l'efficacite d'un echangeur de chaleur dans un boitier d'une installation de climatisation, et boitier de cette installation
IT1196307B (it) *	1984-10-22	1988-11-16	Chiesi Farma Spa	Formulazioni farmaceutiche acquose di piroxicam monoidrato
US5807568A (en) *	1994-12-27	1998-09-15	Mcneil-Ppc, Inc.	Enhanced delivery of topical compositions containing flurbiprofen
IT1283252B1 (it) *	1996-03-15	1998-04-16	Pulitzer Italiana	Soluzioni di piroxicam iniettabili per via parenterale
US6136799A (en) *	1998-04-08	2000-10-24	Abbott Laboratories	Cosolvent formulations
US20020035107A1 (en)	2000-06-20	2002-03-21	Stefan Henke	Highly concentrated stable meloxicam solutions
US8992980B2 (en)	2002-10-25	2015-03-31	Boehringer Ingelheim Vetmedica Gmbh	Water-soluble meloxicam granules
US8314124B2 (en) *	2004-02-06	2012-11-20	Active Biotech Ab	Crystalline salts of quinoline compounds and methods for preparing them
EP1568369A1 (en)	2004-02-23	2005-08-31	Boehringer Ingelheim Vetmedica Gmbh	Use of meloxicam for the treatment of respiratory diseases in pigs
DE102004021281A1 (de) *	2004-04-29	2005-11-24	Boehringer Ingelheim Vetmedica Gmbh	Verwendung von Meloxicam-Formulierungen in der Veterinärmedizin
DE102004030409A1 (de) *	2004-06-23	2006-01-26	Boehringer Ingelheim Vetmedica Gmbh	Neue Verwendung von Meloxicam in der Veterinärmedizin
NZ567627A (en) *	2005-09-30	2011-08-26	Boehringer Ingelheim Vetmed	Granulation process for making a divisible tablet containing meloxicam
SG10201508623RA (en) *	2005-10-19	2015-11-27	Teva Pharma	Crystals of laquinimod sodium, and process for the manufacture thereof
WO2009082471A1 (en) *	2007-12-20	2009-07-02	Teva Pharmaceutical Industries, Ltd.	Stable laquinimod preparations
MX2011002033A (es) *	2008-09-03	2011-05-02	Teva Pharma	2-oxo-1,2-dihidro-quinolinas moduladoras de la funcion inmune.
ES2564931T3 (es) *	2009-07-30	2016-03-30	Teva Pharmaceutical Industries Ltd.	Tratamiento de enfermedad de Crohn con laquinimod
CA2771203C (en) *	2009-08-10	2019-04-09	Teva Pharmaceutical Industries Ltd.	Treatment of bdnf-related disorders using laquinimod
MX2012004177A (es)	2009-10-12	2012-05-08	Boehringer Ingelheim Vetmed	Recipiente para composiciones que comprenden meloxicam.
US9149480B2 (en)	2010-03-03	2015-10-06	Boehringer Ingeleheim Vetmedica GmbH	Use of meloxicam for the long-term treatment of musculoskeletal disorders in cats
US20110218191A1 (en) *	2010-03-03	2011-09-08	Boehringer Ingelheim Vetmedica Gmbh	Use of meloxicam for the long term-treatment of kidney disorders in cats
DE102010014290A1 (de) *	2010-04-08	2011-10-13	Hans Otto Meyer zu Spelbrink	Mittel zur prophylaktischen und therapeutischen Behandlung von Herpes-Infektionen
US9795568B2 (en)	2010-05-05	2017-10-24	Boehringer Ingelheim Vetmedica Gmbh	Low concentration meloxicam tablets
EP2766020A4 (en)	2011-10-12	2015-04-01	Teva Pharma	TREATMENT OF MULTIPLE SCLEROSIS BY COMBINING LAQUINIMOD AND FINGOLIMOD
AR089862A1 (es)	2012-02-03	2014-09-24	Teva Pharma	USO DE LAQUINIMOD PARA EL TRATAMIENTO DE PACIENTES CON ENFERMEDAD DE CROHN EN QUIENES FRACASO UNA TERAPIA ANTI-FACTOR DE NECROSIS TUMORAL a (ANTI-TNFa) DE PRIMERA LINEA
TW201400117A (zh)	2012-06-05	2014-01-01	Teva Pharma	使用拉喹莫德治療眼發炎疾病
MX2015005632A (es)	2012-11-07	2016-02-05	Teva Pharma	Sales de amina de laquinimod.
EP2970129A2 (en)	2013-03-14	2016-01-20	Teva Pharmaceutical Industries Ltd.	Crystals of laquinimod sodium and improved process for the manufacture thereof
KR101749425B1 (ko) *	2015-11-17	2017-06-22	연세대학교 산학협력단	난용성 약물의 서방형 제제
FI3664800T3 (fi) *	2017-08-09	2024-08-07	Dechra Veterinary Products Llc	Cox-2-estäjää käsittäviä terapeuttisia formulaatioita ja niiden käyttötarkoituksia

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5931713A (ja) *	1982-05-08	1984-02-20	ゲデツケ・アクチエンゲゼルシヤフト	オキシカム誘導体含有医薬組成物

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE629650A (2) *	1967-05-18	1900-01-01
US3591584A (en) *	1968-08-27	1971-07-06	Pfizer	Benzothiazine dioxides
DE2602363C2 (de) *	1976-01-22	1984-04-12	Bayer Ag, 5090 Leverkusen	Wäßrige, injizierbare Niclofolan- Formulierungen
DE2756113A1 (de) *	1977-12-16	1979-06-21	Thomae Gmbh Dr K	Neue 4-hydroxy-2h-1,2-benzothiazin- 3-carboxamid-1,1-dioxide, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
AT376879B (de) *	1982-10-27	1985-01-10	Gerot Pharmazeutika	Verfahren zur herstellung einer injektionsloesung

1984
- 1984-10-10 DE DE19843437232 patent/DE3437232A1/de not_active Ceased
1985
- 1985-09-30 EP EP85112378A patent/EP0177870B1/de not_active Expired - Lifetime
- 1985-09-30 DE DE8585112378T patent/DE3582468D1/de not_active Expired - Fee Related
- 1985-09-30 AT AT85112378T patent/ATE62416T1/de not_active IP Right Cessation
- 1985-10-07 US US06/784,903 patent/US4628053A/en not_active Expired - Fee Related
- 1985-10-08 GR GR852439A patent/GR852439B/el unknown
- 1985-10-08 PT PT81264A patent/PT81264B/pt not_active IP Right Cessation
- 1985-10-08 KR KR1019850007399A patent/KR890001001B1/ko not_active Expired
- 1985-10-08 CA CA000492481A patent/CA1251734A/en not_active Expired
- 1985-10-08 JP JP60224617A patent/JPS6191116A/ja active Granted
- 1985-10-09 SU SU853966192A patent/SU1482509A3/ru active
- 1985-10-09 ZA ZA857783A patent/ZA857783B/xx unknown
- 1985-10-09 DD DD85281570A patent/DD238329A5/de not_active IP Right Cessation
- 1985-10-09 HU HU853920A patent/HU195111B/hu not_active IP Right Cessation
- 1985-10-09 NO NO854011A patent/NO166687C/no unknown
- 1985-10-09 NZ NZ213758A patent/NZ213758A/xx unknown
- 1985-10-09 CN CN85107838A patent/CN85107838B/zh not_active Expired
- 1985-10-09 DK DK461385A patent/DK165901C/da not_active IP Right Cessation
- 1985-10-09 IE IE248385A patent/IE58267B1/en not_active IP Right Cessation
- 1985-10-09 AU AU48421/85A patent/AU557184B2/en not_active Ceased
- 1985-10-09 IL IL76624A patent/IL76624A0/xx not_active IP Right Cessation
- 1985-10-09 FI FI853926A patent/FI84315C/fi not_active IP Right Cessation
- 1985-10-09 PH PH32905A patent/PH23058A/en unknown

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS5931713A (ja) *	1982-05-08	1984-02-20	ゲデツケ・アクチエンゲゼルシヤフト	オキシカム誘導体含有医薬組成物

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1998001138A1 (fr) *	1996-07-04	1998-01-15	Nippon Kayaku Kabushiki Kaisha	Injections de succinate sodique de methylprednisolone
JP2003535902A (ja) *	2000-06-20	2003-12-02	ベーリンガーインゲルハイムフェトメディカゲゼルシャフトミットベシュレンクテルハフツング	安定な高濃度メロキシカム溶液
JP2005511720A (ja) *	2001-12-12	2005-04-28	ベーリンガーインゲルハイムフェトメディカゲゼルシャフトミットベシュレンクテルハフツング	無針注射用の安定な高濃度メロキシカム溶液
JP2009539984A (ja) *	2006-06-12	2009-11-19	テバファーマシューティカルインダストリーズリミティド	安定性ラキニモド製剤
JP2010180152A (ja) *	2009-02-05	2010-08-19	Zeria Pharmaceut Co Ltd	コロソリン酸含有水性液剤

Also Published As

Publication number	Publication date
NZ213758A (en)	1988-07-28
EP0177870A3 (en)	1987-06-03
EP0177870A2 (de)	1986-04-16
PT81264A (en)	1985-11-01
FI84315C (fi)	1991-11-25
PT81264B (pt)	1988-02-17
ZA857783B (en)	1987-05-27
DK461385D0 (da)	1985-10-09
IE58267B1 (en)	1993-08-25
NO854011L (no)	1986-04-11
GR852439B (2)	1986-02-10
NO166687B (no)	1991-05-21
CN85107838A (zh)	1986-07-09
DE3437232A1 (de)	1986-04-17
IE852483L (en)	1986-04-10
CN85107838B (zh)	1988-08-24
CA1251734A (en)	1989-03-28
IL76624A0 (en)	1986-02-28
DD238329A5 (de)	1986-08-20
FI853926A0 (fi)	1985-10-09
DK165901B (da)	1993-02-08
DK461385A (da)	1986-04-11
AU557184B2 (en)	1986-12-11
HUT38541A (en)	1986-06-30
DK165901C (da)	1993-06-28
NO166687C (no)	1991-09-04
US4628053A (en)	1986-12-09
FI84315B (fi)	1991-08-15
HU195111B (en)	1988-04-28
ATE62416T1 (de)	1991-04-15
PH23058A (en)	1989-03-27
KR860003013A (ko)	1986-05-19
EP0177870B1 (de)	1991-04-10
AU4842185A (en)	1986-04-17
SU1482509A3 (ru)	1989-05-23
FI853926L (fi)	1986-04-11
DE3582468D1 (de)	1991-05-16
KR890001001B1 (ko)	1989-04-18
JPH03849B2 (2)	1991-01-09

Publication	Publication Date	Title
US4628053A (en)	1986-12-09	Stabilized injectable solutions of piroxicam
FI109659B (fi)	2002-09-30	Levosimendaanin farmaseuttisia liuoksia
US4861786A (en)	1989-08-29	Composition for a stable vein compatible injectable solution of torasemide process for the preparation and method of use
KR960003327B1 (ko)	1996-03-08	디클로페낙과 환상 유기염기와의 염 및 이를 함유한 약학적 조성물
AU599034B2 (en)	1990-07-12	Furosemide salts
US20020169199A1 (en)	2002-11-14	Stabilized carvedilol injection solution
US4360523A (en)	1982-11-23	Pharmaceutical formulations of 4'-(9-acridinylamino)-methanesulfon-m-anisidide
US4880835A (en)	1989-11-14	Oral liquid pharmaceutical compositions of sulindac
JP3720262B2 (ja)	2005-11-24	安定化したカルベジロール注射溶液
AU707220B2 (en)	1999-07-08	Pharmaceutical composition for parenteral application containing an indole-carboxylic acid
EP0397147B1 (en)	1995-01-18	Stable solutions of rebeccamycin analog and preparation thereof
KR920006911B1 (ko)	1992-08-22	안정한 피록시캄 주사액 조성물 및 그의 제조방법
JP2536173B2 (ja)	1996-09-18	注射剤
JPS6146454B2 (2)	1986-10-14
JP4607761B2 (ja)	2011-01-05	溶液医薬組成物
US5034397A (en)	1991-07-23	Stable, water soluble salt compositions of M-AMSA in 1-methyl-2-pyrrolidinone
JPS6350355B2 (2)	1988-10-07
US4425348A (en)	1984-01-10	Antitumor compositions
EP0140492B1 (en)	1989-01-11	L-arginine isoxicamate
US4742082A (en)	1988-05-03	Solution of luprostiol and 1,2,-propanediol and methods of preparation and use
KR100354677B1 (ko)	2002-09-30	염산암프롤륨과 술파퀴녹살린 나트륨을 함유하는 액상 동물용 의약품의 제조방법.
HK1095737B (en)	2011-11-18	Medicinal composition in solution form

JPS6191116A - 安定化された注射用ピロキシカム液剤 - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (2)

Publications (2)

Family

ID=6247603

Family Applications (1)

Country Status (22)

Cited By (5)

Families Citing this family (29)

Citations (1)

Family Cites Families (5)

Patent Citations (1)

Cited By (5)

Also Published As

Similar Documents